Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States

This study describes real-world (RW) treatment patterns, patient characteristics, and outcomes of initial use of covalent Bruton tyrosine kinase inhibitor (cBTKi)-based therapies among patients with Mantle cell lymphoma (MCL). Patients who received at least two lines of therapy and were treated with initial cBTKi-based therapy in second-line (2 L) or later within the nationwide US Flatiron Health electronic health record-derived de-identified database were included (<i>N</i> = 745). Most patients (80.5%) received their initial cBTKi in the 2 L setting. As the initial cBTKi, 67.1% of patients received cBTKi monotherapy; the remainder received a cBTKi combination regimen. From the start date of the line in which the initial cBTKi therapy was received, median time-to-treatment-discontinuation or death, and median time-to-next-treatment or death were 8.0 and 10.8 months, respectively. The 24-month overall survival was 56.5%. In aggressive diseases such as MCL, there continues to be a need for more effective treatment options.